Program

99
92
5
3
2
1
1

Journal Year Published

3
12
16
11
20
10
8
9
10
12
12
10
12
4

Author

149
201
181
139
133
133
125
123
108
105
95
82
78
63
62
54
50
46
43
43

Category

75
47
31
25
6
5
2
2
2
1
1

Keyword

58
43
32
19
18
16
15
15
14
13
13
12
12
12
11
11
10
10
10
9

Journal

16
13
12
5
4
4
4
4
3
3
3
3
3
3
3
2
2
2
2
2

NCATS Publications

High-throughput screening identifies candidate drugs for the treatment of recurrent respiratory papillomatosis.


Alkhilaiwi F, Paul S, Zhou D, Zhang X, Wang F, Palechor-Ceron N, Wilson K, Guha R, Ferrer-Alegre M, Grant N, Thomas C, Schlegel R, Yuan H


Papillomavirus Res , (8), 100181, 2019.

Article Pubmed

Sample image from publication page

Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell-Like Phenotype.


Bian Y, Teper Y, Mathews Griner LA, Aiken TJ, Shukla V, Guha R, Shinn P, Xin HW, Pflicke H, Powers AS, Li D, Jiang J, Patel P, Rogers SA, Aubé J, Ferrer-Alegre M, Thomas C, Rudloff U


Mol. Cancer Ther. , (18), 2097-2110, 2019.

Article Pubmed

Sample image from publication page

(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.


Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, Morris P, Stewart BW, Thomas C, Thompson SM, Moaddel R, Gould TD


Br. J. Pharmacol. , (176), 2573-2592, 2019.

Article Pubmed

Sample image from publication page

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.


Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris P, Thomas C, Moaddel R, Zarate CA, Gould TD


Proc. Natl. Acad. Sci. U.S.A. , (116), 6441-6450, 2019.

Article Pubmed

Sample image from publication page

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.


Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang FH, Schmidt S, Jenne CE, Yuan P, Morris P, Thomas C, Zarate CA, Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Albuquerque EX, Gould TD


Proc. Natl. Acad. Sci. U.S.A. , (116), 5160-5169, 2019.

Article Pubmed

Sample image from publication page

Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( 2R,6R)-hydroxynorketamine.


Highland JN, Morris P, Zanos P, Lovett J, Ghosh S, Wang A, Zarate CA, Thomas C, Moaddel R, Gould TD


J. Psychopharmacol. (Oxford) , 269881118812095, 2018.

Article Pubmed

High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.


Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, McKnight C, Klumpp-Thomas C, Zhang X, Guha R, Hoover S, Simpson RM, Nguyen HM, Corey E, Thomas C, Proia DA, Kelly K


Sci Rep , (8), 17239, 2018.

Article Pubmed

Mutation Profiles in Glioblastoma 3D Oncospheres Modulate Drug Efficacy.


Wilson K, Mathews-Griner LA, Williamson T, Guha R, Chen L, Shinn P, McKnight C, Michael S, Klumpp-Thomas C, Binder ZA, Ferrer-Alegre M, Gallia GL, Thomas C, Riggins GJ


SLAS Technol , 2472630318803749, 2018.

Article Pubmed

Structure-Based Evolution of Low Nanomolar O-GlcNAc Transferase Inhibitors.


Martin SES, Tan ZW, Itkonen HM, Duveau D, Paulo JA, Janetzko J, Boutz PL, Törk L, Moss FA, Thomas C, Gygi SP, Lazarus MB, Walker S


J. Am. Chem. Soc. , (140), 13542-13545, 2018.

Article Pubmed

Sample image from publication page